Literature DB >> 22205241

Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.

Meltem Caglar1, Fani M Bozkurt, Ceren Kapulu Akca, Sezen Elhan Vargol, Miyase Bayraktar, Omer Ugur, Ergun Karaağaoğlu.   

Abstract

INTRODUCTION: The initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high activities of I-131 for postoperative remnant ablation. PATIENTS AND METHODS: A total of 108 nonmetastatic low-risk patients (mean age: 46, 85% women) with papillary and follicular carcinoma had I-131 ablation for the postoperative thyroid remnant. Fifty-three patients received a low dose (L) (800 MBq) and 55 patients received a high dose (H) (3700 MBq) of I-131. After total thyroidectomy, thyroid bed I-131 uptake (RAIU) and neck ultrasonography (USG) were performed to determine the remnant volume and the iodine avidity, which were used to calculate the dose delivered to the remnant tissue. The success rate of I-131 ablation was assessed with four different criteria based on serum thyroglobulin (Tg) and USG with and without the utilization of I-131 diagnostic whole-body scintigraphy (DxWBS). Ablation was considered to be successful if patients fulfilled all of the following criteria. (a) Strict criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or up to 0.2% RAIU, and (iii) Tg < 0.2 ng/ml; (b) lax criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or ≤ 0.2% RAIU, and (iii) Tg < 2 ng/ml; (c) strict criteria based on two tests: (i) USG negative and (ii) Tg < 0.2 ng/ml; (d) lax criteria based on two test: (i) USG negative and (ii) Tg < 2 ng/ml.
RESULTS: When three tests were used to define successful ablation, in group L, 32 out of 53 (60%) and 43 out of 53 (81%) patients were successfully treated versus 35 out of 55 (64%) and 42 out of 55 (76%) for group H on the basis of strict and lax criteria, respectively (P=NS). The differences were not statistically significant between the two groups when only two tests were used to define ablation success (62 vs. 69% with strict and 89 vs. 87% with lax criteria, respectively).
CONCLUSION: Our findings suggest that remnant thyroid tissue in patients with low-risk, well-differentiated thyroid cancer after total thyroidectomy can be ablated with 800 MBq of I-131. The success rate is not different from that obtained with 3700 MBq I-131.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22205241     DOI: 10.1097/MNM.0b013e32834ec5d6

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

Review 1.  Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials.

Authors:  Peizhun Du; Xuelong Jiao; Yanbing Zhou; Yu Li; Shan Kang; Dongfeng Zhang; Jizhun Zhang; Liang Lv; Rajan Patel
Journal:  Endocrine       Date:  2014-07-06       Impact factor: 3.633

2.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

3.  The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

Authors:  Ken Watanabe; Mayuki Uchiyama; Kunihiko Fukuda
Journal:  Jpn J Radiol       Date:  2017-06-15       Impact factor: 2.374

4.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

5.  Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Naoyoshi Onoda; Hitoshi Noguchi; Akira Yoshida
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

6.  Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.

Authors:  Ji Min Han; Won Gu Kim; Tae Yong Kim; Min Ji Jeon; Jin-Sook Ryu; Dong Eun Song; Suck Joon Hong; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

7.  Radiofrequency ablation for postsurgical thyroid removal of differentiated thyroid carcinoma.

Authors:  Dong Xu; Lipin Wang; Bin Long; Xuemei Ye; Minghua Ge; Kejing Wang; Liang Guo; Linfa Li
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

Review 8.  Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Authors:  Y Fang; Y Ding; Q Guo; J Xing; Y Long; Z Zong
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

9.  I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence.

Authors:  Yan Shengguang; Choi Ji-Eun; He Li Lijuan
Journal:  Med Sci Monit       Date:  2016-07-13

10.  Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer.

Authors:  Arun Upadhyaya; Zhaowei Meng; Peng Wang; Guizhi Zhang; Qiang Jia; Jian Tan; Xue Li; Tianpeng Hu; Na Liu; Pingping Zhou; Sen Wang; Xiaoxia Liu; Huiying Wang; Chunmei Zhang; Fengxiao Zhao; Ziyu Yan
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.